Program
QLS4131
A development code. Also written as “QLS4131 for Injection.” and “QLS4131 Injection”.
Its studies are mostly in Multiple Myeloma · Lupus Erythematosus, Systemic, led by Qilu Pharmaceutical.
Furthest: phase 3, since Nov 6, 20263 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 33 open or running | phase 3since Nov 6, 2026 | Jul 8, 2024 | Dec 2026phase 1 · NCT07001839 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 8, 2024First study: phase 1 study in RecurrenceFirst studyNCT06500507 · 90 planned · China
- May 25, 2025Phase 1 study in Lupus Erythematosus, SystemicNCT07001839 · 108 planned
- Nov 6, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07933432 · 300 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Lupus Erythematosus, SystemicNCT07001839
- Dec 14, 2029Primary completion: phase 3 study in RecurrenceNCT07933432
TargetBeta
“The goal of this clinical trial is to learn whether QLS4131, a BCMA/GPRC5D/CD3 trispecific antibody, can improve treatment outcomes when combined with isatuximab in adults with newly diagnosed primary plasma cell leukemia (pPCL).”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| QLS32015rule | Qilu Pharmaceutical | phase 3 | 2 |
| MBS314 for Injectionrule | beijing-mabworks-biotech-co-ltd | phase 2 | 1 |
| REGN17372rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| TQB2029 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07933432Recurrence | 3 | Not yet recruiting | Dec 14, 2029 | 300 |
| NCT07001839Lupus Erythematosus, Systemic | 1 | Not yet recruiting | Dec 2026 | 108 |
| NCT06500507Recurrence · China | 1 | Not yet recruiting | Mar 31, 2026 | 90 |
How it is read
Names in the registry
- “QLS4131”, 1 entry
- “QLS4131 for Injection.”, 1 entry
- “QLS4131 Injection”, 1 entry
Codes read as this program: QLS4131.
Conditions, from the studies’ own filings
- Multiple Myeloma, 2 studies
- Lupus Erythematosus, Systemic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.